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Halothane (2 -bromo-2 -chloro- l , I , 1-trifluoroeth ane) is the most popular inh alation age nt in today's
anesthetic prac tice. Its de sirable properties include
high potency, no nfl ammability, p ati en t acce ptance,
a low incidence of nausea and vomiting, ability to
produce bronchod il atati on, and ease of mainten ance.
Prior to its introduction in 1956, it was subjected
to an intense exa minatio n for bo th general and hepatic toxicity. Although these in vestigati ons disclosed
no evidence of adverse effects, repo rt s of liver
dysfuncti o n after haloth ane administ ra ti o n have appeared constantly in the literat ure. Thus, although
the general safety of this drug continues to be excellent, the clinician is confro nted with a dil emma each
time he elects to use thi s age nt. I ho pe to give some
perspective to this question .
The first thing to und erstand is th at administration of any of the anesthetics currently in use may
be followed by mild and reversible ev idence of liver
derangement. Studies conducted ove r twenty years
ago showed th at administration of diethyl ether or
cyclopropane was followed by significant bromsulfalein retention, a phenomenon also obse rved
when spinal anesth esia was used . Subsequent investigations have shown thi s to be tru e in the case
of methoxyflu rane and haloth ane. Other work has
indicated that clearance of indocya nine gree n ( ICG )
is markedly diminished during anes th es ia. It wo uld
thus appear th at all anesthetics have th e ability to
produce mild and reve rsible ev idence of hepatic
abnorm alities; findings which are probably of no
physiologic significance. This property is shared by
haloth ane.
H alothane also produces reversible abnormalitie s of hepatic mitochondrial functi on. Oxyge n up-
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take of mitochondri a stimul ated by adenosine diphosphate is dimini shed in the presence of clinically
effec ti ve conce nt ration s of haloth ane. Haloth ane,
howeve r, is no different fr om meth oxyfluran e, diethyl
eth er, and ethrane which also produce th ese ch anges.
Thus, altho ugh haloth ane has spec ific metabolic effects , it shares th ese in common with other inh alation
agents.
Perh aps haloth ane exe rts its effects th rough
altered hepatic circulation . Studies performed in man
during haloth ane anesth esia indicate th at splanchnic
blood fl ow decreases as mea n arterial pressure is
lowered; !CG clearance is diminished also. H oweve r, when arteri al ca rbon dioxide tension is elevated, spl anchni c vasodilatation occ urs and splanchnic blood fl ow is increased. In spite of the return
of blood fl o w to norm al, ICG clearance remains
depressed . Cyclopropane, on th e other hand , increases arterial press ure while hepatic blood fl ow
is decreased. Again, ICG clearance is lowered. When
hexa met ho nium is infused, splanchnic vascular resistance dec reases and spl anchnic flow is elevated. As
in th e case of halothane, the return of hepatic perfusion to no rm al does not result in a norm al ICG
clearance . Agai n, we mu st consider the abnormality
in !CG clea rance to be a nonspecific anesthetic effect rath er th an th e pathol ogic manifestation of a
low perfusion state. We mu st also realize th at haloth ane does not have a specific effect, and th at this
phenomeno n is observed with all the inh alation
agents.
It is clear th at the m ajor qu estion which mu st
be answered for any anesthetic agent co ncern s its
ove rall safe ty . It is because of this problem th at a
retrospective stud y of anesthetic safety during th e
yea rs 1959-1963 was undertake n. This study, known
as the N ati onal H aloth ane Study, evalu ated th e
record s of 865,5 15 anesth etics. In this group, I 6,840
deaths were repo rted of which 11 ,289 underwent
autopsy. There were two signific ant questions which
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were posed: ( 1) Were there differences among
anesthetic agents and techniques in overall death
rates and in the incidence of massive hepatic necrosis? (2) Were there any differences among anesthetic agents and techniqu es in the death rate or incidence of massive hepatic necrosis when surgery in
the biliary tract was performed? The overall results
of the study suggested that halothane was at least as
safe as the other agents examined . Furthermore, it
was no less safe th an th e other drugs when biliary
surgery was performed.
Although the data suggested that halothane's
safety was at least equal to th at of other drugs and
techniques, a certain nagging doubt persisted . Most
of the cases of hepatic necrosis were obviously
caused by factors such as hemorrh agic shock, sepsis,
or previous transfusion. However, in nine cases no
etiology was obvious and of these, seve n had received halothane . Furthermore, four of these seven
had been exposed previously to halothane. It must
be realized that the National Halothane Study had
an element of volunteer bias in th at several of the
unexpl ained cases of massive hepatic necrosis had
already been published, and most probably the
institution volunteered to participate in the study
because of this. Nonetheless, the possibility was considered th at halothane might be responsible for certain cases of hepat ic dys function .
In subsequent years, a number of events were
reported which indicated th at exposure of unoperated
man to extremely low concentrations of the agent
might rarely produce hepatic abnormalities. It was
from a consideration of such events that the concept of halothane hypersensitivity arose. This theory
stated that halothane is not a direct hepatotoxin. In
the rare cases (the incidence of unexplained hep atic
necrosis following halothane was 1 :35,000), the individual might be hypersensitive or "allergic" to the
agent. This would explain the increased likelihood of
observing the phenomenon after more than one exposure, and might also explain the occurrence in unoperated man receiving sub- anesthetic concentrations
of the drug. Additional support to this theory was
evidence of lymphocyte transformation produced by
incubating lymphocytes of affected man with halothane. It should be noted that many individu als with
what appears to be halothane-i nduced hepatitis did
not show positive lymphocyte transformation. Furthermore, occasional false positive results have been
reported . Thus, although the hypersensitivity theory
is not unreasonable, it should not be considered to
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be the sole explanation of this unfortunate phenomenon.
We have recently studied the concentrations of ·
immunoglobulins in man following surgery per- .
formed during halothane anesthesia. Observations
were made prior to and up to 30 days after surgery;
data obtained was compared with similar studies
when anesthesia was provided by nitrous oxide supplemented with narcotic. No significant changes
were produced by either nitrous oxide-narcotic or
nitrous oxide-halothane. In another group of individuals receiving haloth ane anesthesia, measurements of serum glutamic oxaloacetic transaminase
concentratibn and bromsulfalein retention accompanied the assays of immunoglobulin concentrations.
Although transient abnormalities of hepatic function
were observed, no alterations in the immunoglobulin
pattern were noted during observations lasting as
long as 60 days.
Although these data do not definitely rule out
an immunologic basis for halothane-induced hepatic
necrosis, they do suggest that a systematic immunologic abnormality does not occur usually following anesthesia with this agent. Furthermore , they
indicate that short-lived abnormalities of hepatic
function following halothane anesthesia are similar
to those observed with other anesthetic drugs and
are not the result of immunologic factors . Finally,
these observations furnish a base line should the
opportunity arise to obtain samples from a patient
with severe hepatic failure following halothane anesthesia.
Are there any other mechanisms which might
be responsible? In the past few years, increasing
emphasis has been placed on the ability of the hepatic microsomal system to detoxify a wide variety
of drugs. Many of the inhalation anesthetics, among
th em halothane, are so metabolized . Furthermore,
prior exposure to haloth ane produces enzyme induction which results in a more rapid rate of haloth ane biodegradation. It is not inconceivable th at
abnormal pathways of biodegradation might produce
toxic metabolites which could result in hepatic necrosis.
At the present time, the evidence is not clear as
to what might be the mech anism for the extremely
rare case of halothane-ind uced hepatic necrosis. Indeed , it is still a moot point as to whether this entity
can be definitely proven to exist. However, the
answer to th e question of this lecture can be easily
made. The N ational H alothane Study supplied excel-
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Jent data indicating that in the overwhelming majority of patients the drug is as safe as any currently
used. I would sugges t th at th e mai n factor determining
patient safety is th e individual ad mini stering the
anesthetic rather than th e specific age nt itself. However, although the drug is exceedingly safe, a small
number of patients may be at risk . It is th e tas k of
future investigation to delineate th ese individuals so
as to prevent the occurrence of thi s sy ndrom e.
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